Prenatal Testing and Newborn Screening Market

Prenatal Testing and Newborn Screening Market Overview

The global non-invasive prenatal testing and newborn screening market is likely be worth $8.2 billion by 2027, representing a CAGR of 15%. It has been estimated that close to 131 million babies are born each year across the globe. Of these, approximately 7.9 million are born with birth defects. In fact, more than 7,000 genetic disorders have been identified so far and the number is rising.Genetic testing solutions that enable early detection of genetic abnormalities in fetuses and newborns are important to ensure that the person does not face complications later in life. With the emergence of innovative diagnostic and screening techniques, several methods of genetic testing have become popular. These include carrier testing, preimplantation genetic diagnosis / screening (PGD / PGS), prenatal testing, paternity testing and newborn screening. Amongst these, prenatal testing (primarily Non-invasive prenatal testing (NIPT)) and newborn screening have gained relatively more traction in prenatal and neonatal care.

Specifically, NIPT has emerged as an efficient screening method in prenatal care that can analyze the cell-free DNA (cfDNA) extracted from maternal blood sample during pregnancy. NIPTs offer several advantages over conventional prenatal testing procedures; in addition to being non-invasive, these tests offer shorter turnaround times and high accuracy. It has been reported that the increasing popularity of NIPTs has led to a 50% decline in the use of invasive prenatal testing procedures (such as amniocentesis and chorionic villus sampling (CVS)). With the changing mindset of people belonging to different cultural and socio-economic background, the uptake of NIPTs is likely to increase further. Moreover, with the rising awareness and availability of NIPTs designed for a wide array of disease indications, and development of innovative and versatile technologies, we expect that the interest will continue to grow.

Within neonatal care, the emergence of advanced technologies in this domain has reflected a gradual rise in the overall development of advanced newborn screening tests in the last few years. In fact, public service bodies in more than 70 countries across the globe have facilitated the establishment of newborn screening programs in their respective countries. With an already established platform, we expect the overall newborn screening market to continue its gradual rise driven by higher adoption, competitive prices and availability of these tests in various geographies across the globe.

Recent Developments Non-Invasive Prenatal Testing and Newborn Screening Market

• In May 2026, Natera announced an enhanced version of its Panorama non-invasive prenatal test using SNP-informed deep sequencing technology. The update significantly improves performance in low fetal fraction samples, reducing the no-call rate to 0.5%.
• In March 2026, The Delhi government launched the ANMOL scheme, a large-scale newborn screening initiative offering free testing for 56 genetic and metabolic disorders across public and private hospitals. The program aims to improve early detection and reduce infant mortality by enabling timely interventions, positioning India’s capital among regions expanding population-wide newborn screening infrastructure.
• In February 2026, BillionToOne launched expanded UNITY non-invasive prenatal tests covering red blood cell and platelet fetal antigens, targeting conditions such as HDFN and FNAIT. The tests, the first of their kind in the U.S., demonstrate over 99.9% sensitivity and specificity and expand prenatal screening capabilities for antigen incompatibilities affecting up to 2.5% of pregnancies.
• In January 2026, Natera launched its 21-gene Fetal Focus single-gene non-invasive prenatal test, supported by results from the EXPAND clinical trial. The test demonstrated 96% sensitivity and 98% specificity across 294 samples, enabling earlier detection of inherited conditions using maternal blood and expanding the scope of prenatal genetic screening panels.

Scope of the Report

The “Global Non-Invasive Prenatal Testing and Newborn Screening Market, 2017-2027” market report features an extensive study on the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the non-invasive prenatal testing and newborn screening market. NIPT and newborn screening tests are designed for the detection of different types of genetic abnormalities in fetuses and newborns. Detection of genetic disorders in prenatal and neonatal stages is critical tolower the child mortality rates. Moreover, early detection, treatment and management of these genetic disorders is important to avoid serious health problems at later stages in life. The market research report offers a comprehensive discussion on the future potential of these tests in prenatal and neonatal care.

Ever since the launch and subsequent success of the first NIPT, the NIFTY® test (launched by BGI in August 2011), several firms have taken initiatives to develop and commercialize NIPTs. Currently, a number of NIPTs that are designed to screen for conditions such as chromosomal abnormalities, sex chromosomal abnormalities and microdeletion syndromes are available in the market.In addition, many companies have entered into collaborations to distribute these tests across various geographies in order to expand the availability to a wider population. Examples of popular NIPT tests include Harmony® test(Ariosa Diagnostics, acquired by Roche), PraenaTest® / PrenaTest® (LifeCodexx, a subsidiary of GATC Biotech), Panorama® (Natera®), NIFTY® (BGI), Verifi® (Verinata Health, acquired by Illumina®), VisibiliT^TM (Sequenom^TM, acquired by LabCorp®) and IONA® test / Safe NIPT (Premaitha Health).

The advent of routine newborn screening in the 1960s for the detection of phenylketonuria (PKU) established the role and importance of newborn screening in mitigating disorders in newborns. The field is continuously evolving as the awareness related to benefits of newborn screening increases. Moreover, introduction of advanced technologies such as next-generation sequencing (NGS) and tandem mass spectroscopy has notably accelerated the development in this domain. Newborn screening diagnostics are primarily available for conditions such as metabolic disorders, endocrine disorders, hemoglobin disorders, congenital heart disorders and hearing disorders.

Both prenatal testing and newborn screening offer several benefits in terms of disease management in neonatal care and has gathered interest from a wide range of companies worldwide. In total, we have identified 76 NIPT tests and 38 advanced newborn screening tests. In addition, there are several companies that are engaged in the development of basic tests, devices, systems and technology platforms for both prenatal testing and newborn screening. One of the key objectives of this market report was to understand the current activity and the future potential of the NIPT and newborn screening markets. Amongst other elements, the market research report covers the following:

NIPT:

• The overall landscape of NIPT tests with respect to the stage of development, sample type, technology platforms, type of indications, stage of pregnancy and result turnaround time. In addition, the market report provides a detailed discussion and analysis on the various innovative technology platforms available for the development of NIPTs and the indications screened.
• Comprehensive profiles of the leading players in the field of NIPT and their products, highlighting details of the company, financial and funding information (if available), product portfolio and a comprehensive future outlook. Likewise, the product profiles provide information on the product and their development history, technology platforms, test procedure, specifications, advantages and clinical information (if available).
• An elaborate geographical coverage analysis of the NIPT tests available / under development across the globe, a comparative heat map analysis of NIPTs (on the basis of sensitivity, specificity, result turnaround time and stage of pregnancy when the test can be performed), harvey ball analysis highlighting the panel strength of each test based on the number of indications being screened, and the geographical distribution of the companies involved in the development of NIPTs.

Newborn Screening:

• The overall landscape of newborn screening tests with respect to the stage of development, screening type, technology platform, type of indication, period of sample collection after birth and result turnaround time.
• Detailed profiles of the players involved in the field of newborn screening and their products highlighting details on the company, financial and funding information (if available), product portfolio and a comprehensive future outlook. Likewise, the product profiles provide information on the product specifications and test methodology. In addition, the market report includes a comprehensive list of the core and secondary disorders / deficiencies recommended for newborn screening.
• An illustrative grid representation of the newborn screening tests based on screening type (basic newborn screening, expanded newborn screening, comprehensive newborn screening and advanced newborn screening) and technology platform, and an overview of the landscape of industry developers (start-ups, mid-sized and large-sized players).

Additionally, the market research report includes:

• A detailed discussion of the existing regulatory landscape in the field of NIPT and the current status of the government mandated newborn screening programs established in various countries across the globe to provide proper medical care to newborns.
• Partnerships that have been recently been inked amongst different stakeholders, covering product distribution / marketingagreements, development / commercialization agreements and mergers / acquisitions.
• A detailed survey analysis primarily focused on gaining additional insights on the company’s tests or services, highlighting the focus area of the company, type of the products, purpose and commercial availability of the lead product(s).

The key objective of xyz market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for xyz market during the forecast period. We have provided insights on the likely regional evolution of the NIPT market across patients in three risk group segments (high risk, average risk and low risk) covering North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe) Asia (Japan, China and India) and rest of the world. In addition, we have provided the likely distribution by type of indications, stage of pregnancy when the test can be conducted and the share of individual NIPTs. The market forecast takes into account the impending price variations that are likely to emerge in the mid-long term as a result of growing adoption and increased competition. In order to account for uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different market forecast scenarios, depicting conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this market research report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data and primary research discussions. For the purpose of the market report, we invited over 150 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this market research report were also influenced by discussions conducted with experts in non-invasive prenatal testing and newborn screening market. These include contributions from Jim Patterson (Vice President, Sales and Marketing North America, EvolveGene®), Osama Fikry (Metabolic and Diagnostic Head, NewBridge Pharmaceuticals) and Silke Arndt (Medical Scientist and NGS Manager, Inqaba Biotec).All financial figures mentioned in this market research report are in USD, unless otherwise specified.